FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to antisense oligonucleotides and can be used in medicine. Invention discloses a novel antisense oligonucleotide for modifying pre-mRNA splicing at the receptor of advanced glycation end products (RACE). Antisense oligonucleotides according to the present invention are capable of selectively reducing the expression of pro-inflammatory transmembrane RAGE (mRAGE; RAGE containing exon 10), simultaneously increasing expression of extracellular soluble RAGE (esRAGE; exon 10 skipping leads to preservation of intron 9b).
EFFECT: invention can be used in medicine for treating, preventing or relieving the effects of the disease associated with RAGE expression.
36 cl, 5 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION | 2016 |
|
RU2736574C2 |
| COMPOUND FOR MODULATION OF C9ORF72 GENE EXPRESSION AND USE THEREOF | 2013 |
|
RU2730677C2 |
| NEW METHOD OF TREATING RETINITIS PIGMENTOSA | 2020 |
|
RU2817702C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2747734C2 |
| TREATMENT OF TUMORS OF DISEASES RELATED TO THE GENOM-SUPPRESSOR BY THERAPY OF NATURAL TRANSCRIPT INHIBITION IN ANTI-SIGNIFICANT ORIENTATION REGARDING THIS GENE | 2009 |
|
RU2746478C2 |
| MODULATION OF FACTOR 11 EXPRESSION | 2014 |
|
RU2739594C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2777570C2 |
| SYSTEM OF TARGETED SPLICING CHANGES IN MARK2 GENE | 2023 |
|
RU2810907C1 |
| MYOSTATIN SIGNAL INHIBITOR | 2019 |
|
RU2820270C2 |
| COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT | 2019 |
|
RU2793459C2 |
